The manufacturer of the specific Lenvaxen product.
It is essential to distinguish this unanswered product-specific question from the independently documented history of lenvatinib.
Original developer of lenvatinib
Eisai states that it discovered and developed lenvatinib in-house. The medicine became associated with the reference brand LENVIMA.
Reference product
LENVIMA is an established lenvatinib product. The FDA identifies LENVIMA as a lenvatinib capsule product and records its initial U.S. approval in 2015.
European relationship
In the European Union, Lenvima is authorized for specified differentiated thyroid carcinoma and hepatocellular carcinoma indications. Lenvatinib is also marketed as Kisplyx for specified renal-cell-carcinoma uses. The EMA lists Eisai GmbH as the marketing authorization holder for Lenvima and Kisplyx.
Why manufacturer identity matters
The company that developed an active ingredient does not necessarily manufacture every later product containing that ingredient. A manufacturer, brand owner, marketing authorization holder, distributor and supplier can be separate entities.
Accordingly, no company should be identified as the Lenvaxen manufacturer without product-specific documentation.
Quality information
Specific GMP certification, manufacturing site, batch-release arrangements or quality certifications for Lenvaxen .
Official company information
For the reference product, official information about Eisai can be accessed through its corporate resources. Lenvaxen-specific corporate information requires verification.